RNS
REACH: non-regulatory announcement
TheraCryf
plc
("TheraCryf", the "Company" or the "Group")
Investor
Webinar
Alderley Park, UK - 26 March 2025:
TheraCryf plc (AIM: TCF), the clinical stage drug development
company focussing on oncology and neuropsychiatry, announces that
Dr Huw Jones, Chief Executive Officer, and Dr Alastair Smith,
Non-executive Chair, will be hosting an investor
webinar on Wednesday, 2 April 2025 at 6.00
pm (BST).
The webinar is open to all existing
and potential investors and will focus on the Company's plans to
drive its Ox-1 addiction and SFX-01 glioblastoma programmes,
following the fundraise which completed earlier this month.
These funds will enable the Company to take the Orexin-1 antagonist
to the key inflection point of clinical trial readiness, allowing
it to unlock potential commercial opportunities.
There will be a Q&A session
after the presentation and questions can be pre-submitted as part
of the registration process. You can
register for the event for free at:
https://www.turnerpope.com/register/
The webinar will be chaired by
experienced news and corporate events presenter, Katie Pilbeam and
hosted by TheraCryf's joint broker, Turner Pope
Investments.
A more detailed presentation about
Orexin-1, the market opportunity and the science behind the
programme will be held in May.
Enquiries
|
TheraCryf plc
Dr Huw Jones, CEO
Toni Hänninen, CFO
Dr Helen Kuhlman, CBO
|
+44
(0)1625 315 090
enquiries@theracryf.com
|
|
Turner Pope Investments (Joint Broker)
James Pope / Andy
Thacker
Cavendish Capital Markets (NOMAD & Joint
Broker)
Geoff Nash / Teddy
Whiley / Rory Sale (Corporate Finance)
Nigel Birks / Harriet Ward (ECM)
|
+44
(0)20 3657 0050
+44
(0)20 7220 0500
|
|
|
|
| Vigo Consulting
Rozi Morris
|
+44 (0)20 7390
0231
theracryf@vigoconsulting.com
|
|
|
About TheraCryf plc
TheraCryf is the clinical stage drug
development company focussing on oncology and neuropsychiatry. The
Company has a broad clinical and preclinical pipeline in
indications including glioblastoma* neurodevelopmental disorders,
addiction, anxiety and narcolepsy [*orphan indication].
The Company's strategy is to
generate compelling data sets to preclinical and/or clinical proof
of concept and partner its clinical programmes with mid-size to
large pharma for larger trials and commercialisation. As well as a
number of industry partnerships with companies, including Stalicla
SA, in neurodevelopmental disorders. The Company has sourced
know how for programmes from companies such as Shire (now
Takeda).
TheraCryf has worked with and has
ongoing collaborations with major universities and hospitals such
as the University of Manchester, La Sapienza (Università di Roma),
the Erasmus Medical Centre, Rotterdam, Kings College London and the
University of Michigan.
The Company has its headquarters and
registered office at Alderley Park, Cheshire. It is quoted on AIM
in London and trades under the ticker symbol TCF. 
For further information, please
visit: www.theracryf.com.
